Supplemental Figure 2 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma

Authors:

Abstract
Gating strategy for analysis of live lymphocytes.